Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
Oppenheimer Maintains Outperform on Protara Therapeutics, Raises Price Target to $34
Oppenheimer analyst Leland Gershell maintains Protara Therapeutics (NASDAQ:TARA) with a Outperform and raises the price target from $32 to $34.
ArTara Therapeutics Q3 EPS $(0.96) Up From $(1.26) YoY
ArTara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.96) per share. This is a 23.81 percent increase over losses of $(1.26) per share from the same period last year.
Why Protara Therapeutics Stock Is Rising Today
Protara Therapeutics Inc (NASDAQ: TARA) is trading higher Tuesday after the company announced FDA clearance of the Investigational New Drug application for TARA-002 for the treatment of non-muscle invasive bladder cancer.
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 11)
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers
Viridian Therapeutics (NASDAQ:VRDN) stock rose 22.49% to $19.17 during Tuesday's pre-market session. The company's market cap stands at $331.8 million.
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 6)
